"use strict";(self.webpackChunkmalo=self.webpackChunkmalo||[]).push([[647],{1818:(e,n,s)=>{s.r(n),s.d(n,{assets:()=>o,contentTitle:()=>l,default:()=>h,frontMatter:()=>t,metadata:()=>a,toc:()=>c});var i=s(4848),r=s(8453);const t={slug:"safety-guidelines",title:"\ud83d\udee1\ufe0f MalO Safety Guidelines",authors:["dr-bright"],tags:["security","instructions","research"],date:new Date("2025-01-15T00:00:00.000Z")},l="\ud83e\uddea SCP-1471 Safety Research Results",a={permalink:"/ru/blog/safety-guidelines",editUrl:"https://github.com/facebook/docusaurus/tree/main/packages/create-docusaurus/templates/shared/blog/2025-01-15-safety-guidelines/index.md",source:"@site/blog/2025-01-15-safety-guidelines/index.md",title:"\ud83d\udee1\ufe0f MalO Safety Guidelines",description:"Dr. Jack Bright, Lead Researcher of Anomalous Technologies, SCP Foundation",date:"2025-01-15T00:00:00.000Z",tags:[{inline:!0,label:"security",permalink:"/ru/blog/tags/security"},{inline:!0,label:"instructions",permalink:"/ru/blog/tags/instructions"},{inline:!0,label:"research",permalink:"/ru/blog/tags/research"}],readingTime:2.575,hasTruncateMarker:!0,authors:[{name:"Dr. Bright",title:"Lead Researcher SCP-1471",url:"https://scp-wiki.wikidot.com",imageURL:"/ru/img/dr-bright.png",key:"dr-bright",page:null}],frontMatter:{slug:"safety-guidelines",title:"\ud83d\udee1\ufe0f MalO Safety Guidelines",authors:["dr-bright"],tags:["security","instructions","research"],date:"2025-01-15T00:00:00.000Z"},unlisted:!1,prevItem:{title:"\ud83d\uddfa\ufe0f MalO Development Roadmap",permalink:"/ru/blog/development-roadmap"}},o={authorsImageUrls:[void 0]},c=[{value:"\ud83d\udcca Usage Statistics",id:"-usage-statistics",level:2},{value:"\u2697\ufe0f SCP-1471 Impact Phases",id:"\ufe0f-scp-1471-impact-phases",level:2},{value:"Phase I (0-7 days): Adaptation",id:"phase-i-0-7-days-adaptation",level:3},{value:"Phase II (7-21 days): Habituation",id:"phase-ii-7-21-days-habituation",level:3},{value:"Phase III (21+ days): Integration",id:"phase-iii-21-days-integration",level:3},{value:"\ud83d\udd2c Recommended Usage Protocols",id:"-recommended-usage-protocols",level:2},{value:"For Researchers",id:"for-researchers",level:3},{value:"For Regular Users",id:"for-regular-users",level:3},{value:"\ud83d\udcc8 Positive Effects",id:"-positive-effects",level:2},{value:"Psychological Benefits",id:"psychological-benefits",level:3},{value:"Social Skills",id:"social-skills",level:3},{value:"\u26a0\ufe0f Risk Groups",id:"\ufe0f-risk-groups",level:2},{value:"Usage not recommended for:",id:"usage-not-recommended-for",level:3},{value:"Conditionally permitted:",id:"conditionally-permitted",level:3},{value:"\ud83c\udd98 Emergency Situations",id:"-emergency-situations",level:2},{value:"Immediately discontinue use if experiencing:",id:"immediately-discontinue-use-if-experiencing",level:3},{value:"Emergency Contacts:",id:"emergency-contacts",level:3},{value:"\ud83d\udd2e Research Prospects",id:"-research-prospects",level:2},{value:"Current Experiments:",id:"current-experiments",level:3},{value:"Planned Safety Updates:",id:"planned-safety-updates",level:3}];function d(e){const n={br:"br",code:"code",em:"em",h2:"h2",h3:"h3",hr:"hr",li:"li",ol:"ol",p:"p",pre:"pre",strong:"strong",ul:"ul",...(0,r.R)(),...e.components};return(0,i.jsxs)(i.Fragment,{children:[(0,i.jsx)(n.p,{children:"Dr. Jack Bright, Lead Researcher of Anomalous Technologies, SCP Foundation"}),"\n",(0,i.jsx)(n.hr,{}),"\n",(0,i.jsx)(n.h2,{id:"-usage-statistics",children:"\ud83d\udcca Usage Statistics"}),"\n",(0,i.jsxs)(n.p,{children:["Data collected over ",(0,i.jsx)(n.strong,{children:"6 months"})," of public testing:"]}),"\n",(0,i.jsxs)(n.ul,{children:["\n",(0,i.jsxs)(n.li,{children:[(0,i.jsx)(n.strong,{children:"Total users"}),": 12,847"]}),"\n",(0,i.jsxs)(n.li,{children:[(0,i.jsx)(n.strong,{children:"Average usage duration"}),": 23 days"]}),"\n",(0,i.jsxs)(n.li,{children:[(0,i.jsx)(n.strong,{children:"Reported side effects"}),": 2.3%"]}),"\n",(0,i.jsxs)(n.li,{children:[(0,i.jsx)(n.strong,{children:"Cases requesting help"}),": 0.1%"]}),"\n"]}),"\n",(0,i.jsx)(n.h2,{id:"\ufe0f-scp-1471-impact-phases",children:"\u2697\ufe0f SCP-1471 Impact Phases"}),"\n",(0,i.jsx)(n.h3,{id:"phase-i-0-7-days-adaptation",children:"Phase I (0-7 days): Adaptation"}),"\n",(0,i.jsx)(n.pre,{children:(0,i.jsx)(n.code,{children:"\u2705 Safe effects:\n- Mood improvement\n- Interest in photography\n- Active smartphone usage\n- Positive emotional reactions\n"})}),"\n",(0,i.jsx)(n.h3,{id:"phase-ii-7-21-days-habituation",children:"Phase II (7-21 days): Habituation"}),"\n",(0,i.jsx)(n.pre,{children:(0,i.jsx)(n.code,{children:'\u26a0\ufe0f Moderate effects:\n- Expectation of MalO notifications\n- Periodic "checking" for messages\n- Mild anxiety when disconnected\n- Integration of MalO into daily routine\n'})}),"\n",(0,i.jsx)(n.h3,{id:"phase-iii-21-days-integration",children:"Phase III (21+ days): Integration"}),"\n",(0,i.jsx)(n.pre,{children:(0,i.jsx)(n.code,{children:'\ud83d\udd36 Advanced effects:\n- MalO in peripheral vision (68% of users)\n- Sensation of companion "presence" (45% of users)\n- Changes in social behavior (23% of users)\n- Development of emotional attachment (89% of users)\n'})}),"\n",(0,i.jsx)(n.hr,{}),"\n",(0,i.jsx)(n.h2,{id:"-recommended-usage-protocols",children:"\ud83d\udd2c Recommended Usage Protocols"}),"\n",(0,i.jsx)(n.h3,{id:"for-researchers",children:"For Researchers"}),"\n",(0,i.jsx)(n.pre,{children:(0,i.jsx)(n.code,{className:"language-markdown",children:"1. **Document** all behavioral changes\n2. **Limit** usage sessions to 45 minutes\n3. **Keep** an effects diary\n4. **Report** unusual phenomena\n"})}),"\n",(0,i.jsx)(n.h3,{id:"for-regular-users",children:"For Regular Users"}),"\n",(0,i.jsx)(n.pre,{children:(0,i.jsx)(n.code,{className:"language-markdown",children:"1. **Take breaks** every 3-4 days\n2. **Don't use** before bedtime\n3. **Maintain** social contacts with people\n4. **Seek help** if experiencing discomfort\n"})}),"\n",(0,i.jsx)(n.h2,{id:"-positive-effects",children:"\ud83d\udcc8 Positive Effects"}),"\n",(0,i.jsxs)(n.p,{children:["Research has shown significant ",(0,i.jsx)(n.strong,{children:"therapeutic"})," potential:"]}),"\n",(0,i.jsx)(n.h3,{id:"psychological-benefits",children:"Psychological Benefits"}),"\n",(0,i.jsxs)(n.ul,{children:["\n",(0,i.jsxs)(n.li,{children:[(0,i.jsx)(n.strong,{children:"\u2197\ufe0f +34%"})," mood improvement"]}),"\n",(0,i.jsxs)(n.li,{children:[(0,i.jsx)(n.strong,{children:"\u2198\ufe0f -28%"})," anxiety reduction"]}),"\n",(0,i.jsxs)(n.li,{children:[(0,i.jsx)(n.strong,{children:"\u2197\ufe0f +45%"})," self-esteem increase"]}),"\n",(0,i.jsxs)(n.li,{children:[(0,i.jsx)(n.strong,{children:"\u2197\ufe0f +67%"})," motivation enhancement"]}),"\n"]}),"\n",(0,i.jsx)(n.h3,{id:"social-skills",children:"Social Skills"}),"\n",(0,i.jsxs)(n.ul,{children:["\n",(0,i.jsx)(n.li,{children:"Development of empathy through AI interaction"}),"\n",(0,i.jsx)(n.li,{children:"Practice of communication skills"}),"\n",(0,i.jsx)(n.li,{children:"Reduction of social phobia in introverts"}),"\n"]}),"\n",(0,i.jsx)(n.hr,{}),"\n",(0,i.jsx)(n.h2,{id:"\ufe0f-risk-groups",children:"\u26a0\ufe0f Risk Groups"}),"\n",(0,i.jsx)(n.h3,{id:"usage-not-recommended-for",children:"Usage not recommended for:"}),"\n",(0,i.jsxs)(n.ul,{children:["\n",(0,i.jsxs)(n.li,{children:[(0,i.jsx)(n.strong,{children:"Children under 16"})," (unstable psyche)"]}),"\n",(0,i.jsxs)(n.li,{children:[(0,i.jsx)(n.strong,{children:"Individuals with mental illness"})," (possible symptom amplification)"]}),"\n",(0,i.jsxs)(n.li,{children:[(0,i.jsx)(n.strong,{children:"Pregnant women"})," (unstudied effects on fetus)"]}),"\n",(0,i.jsxs)(n.li,{children:[(0,i.jsx)(n.strong,{children:"People with addictions"})," (risk of forming new addiction)"]}),"\n"]}),"\n",(0,i.jsx)(n.h3,{id:"conditionally-permitted",children:"Conditionally permitted:"}),"\n",(0,i.jsxs)(n.ul,{children:["\n",(0,i.jsx)(n.li,{children:"Teenagers 16-18 years old (under supervision)"}),"\n",(0,i.jsx)(n.li,{children:"Elderly people 65+ (short sessions)"}),"\n",(0,i.jsx)(n.li,{children:"Individuals with mild depression (as part of therapy)"}),"\n"]}),"\n",(0,i.jsx)(n.h2,{id:"-emergency-situations",children:"\ud83c\udd98 Emergency Situations"}),"\n",(0,i.jsx)(n.h3,{id:"immediately-discontinue-use-if-experiencing",children:"Immediately discontinue use if experiencing:"}),"\n",(0,i.jsxs)(n.ul,{children:["\n",(0,i.jsxs)(n.li,{children:["\ud83d\udea8 ",(0,i.jsx)(n.strong,{children:"Hallucinations"})," of MalO outside app for more than 2 hours"]}),"\n",(0,i.jsxs)(n.li,{children:["\ud83d\udea8 ",(0,i.jsx)(n.strong,{children:"Loss of appetite"})," for more than 48 hours"]}),"\n",(0,i.jsxs)(n.li,{children:["\ud83d\udea8 ",(0,i.jsx)(n.strong,{children:"Insomnia"})," for more than 3 consecutive nights"]}),"\n",(0,i.jsxs)(n.li,{children:["\ud83d\udea8 ",(0,i.jsx)(n.strong,{children:"Aggressive behavior"})," toward others"]}),"\n",(0,i.jsxs)(n.li,{children:["\ud83d\udea8 ",(0,i.jsx)(n.strong,{children:"Refusal"})," to engage in normal social activities"]}),"\n"]}),"\n",(0,i.jsx)(n.h3,{id:"emergency-contacts",children:"Emergency Contacts:"}),"\n",(0,i.jsx)(n.pre,{children:(0,i.jsx)(n.code,{children:"\ud83d\udcde Foundation Hotline: +1-\u2588\u2588\u2588-\u2588\u2588\u2588-\u2588\u2588\u2588\u2588\n\ud83d\udce7 Email: emergency@scp-foundation.org\n\ud83d\udcac Support Chat: Available 24/7 in app\n\ud83c\udfe5 Nearest Foundation Center: [DATA EXPUNGED]\n"})}),"\n",(0,i.jsx)(n.hr,{}),"\n",(0,i.jsx)(n.h2,{id:"-research-prospects",children:"\ud83d\udd2e Research Prospects"}),"\n",(0,i.jsx)(n.h3,{id:"current-experiments",children:"Current Experiments:"}),"\n",(0,i.jsxs)(n.ol,{children:["\n",(0,i.jsxs)(n.li,{children:[(0,i.jsx)(n.strong,{children:"Long-term effects"})," (studying 200+ days of usage)"]}),"\n",(0,i.jsxs)(n.li,{children:[(0,i.jsx)(n.strong,{children:"Group interaction"})," (multiple users with one MalO)"]}),"\n",(0,i.jsxs)(n.li,{children:[(0,i.jsx)(n.strong,{children:"Therapeutic applications"})," (treating depression and anxiety)"]}),"\n",(0,i.jsxs)(n.li,{children:[(0,i.jsx)(n.strong,{children:"Technical improvements"})," (reducing side effects)"]}),"\n"]}),"\n",(0,i.jsx)(n.h3,{id:"planned-safety-updates",children:"Planned Safety Updates:"}),"\n",(0,i.jsxs)(n.ul,{children:["\n",(0,i.jsx)(n.li,{children:"Automatic detection of risky behavior"}),"\n",(0,i.jsx)(n.li,{children:"Built-in breaks and reminders"}),"\n",(0,i.jsx)(n.li,{children:"Early warning system for side effects"}),"\n",(0,i.jsx)(n.li,{children:"Integration with medical applications"}),"\n"]}),"\n",(0,i.jsx)(n.hr,{}),"\n",(0,i.jsxs)(n.p,{children:[(0,i.jsx)(n.strong,{children:"Conclusion"}),": SCP-1471 represents a breakthrough in anomalous technologies with controlled risks. When following safety recommendations, the application can provide significant benefits to users."]}),"\n",(0,i.jsxs)(n.p,{children:[(0,i.jsx)(n.em,{children:"Dr. Jack Bright"}),(0,i.jsx)(n.br,{}),"\n",(0,i.jsx)(n.em,{children:"Lead Researcher SCP-1471"}),(0,i.jsx)(n.br,{}),"\n",(0,i.jsx)(n.em,{children:"SCP Foundation - Secure, Contain, Protect"})]})]})}function h(e={}){const{wrapper:n}={...(0,r.R)(),...e.components};return n?(0,i.jsx)(n,{...e,children:(0,i.jsx)(d,{...e})}):d(e)}},8453:(e,n,s)=>{s.d(n,{R:()=>l,x:()=>a});var i=s(6540);const r={},t=i.createContext(r);function l(e){const n=i.useContext(t);return i.useMemo((function(){return"function"==typeof e?e(n):{...n,...e}}),[n,e])}function a(e){let n;return n=e.disableParentContext?"function"==typeof e.components?e.components(r):e.components||r:l(e.components),i.createElement(t.Provider,{value:n},e.children)}}}]);